Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2022 May 16

PMID 35570988

Authors

Xiaolei Zhou

Eric Davenport

John Ouyang

Molly E Hoke

Diana Garbinsky

Indra Agarwal

Holly B Krasa

Dorothee Oberdhan

Affiliations

Soon will be listed here.

Abstract

Introduction: In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also evaluated effects on total kidney volume (TKV); slowing of TKV growth was demonstrated. Subjects were followed in open-label extension trials. To characterize longer-term effects of treatment, an analysis was conducted comparing tolvaptan-treated subjects with subjects from standard of care (SOC) ADPKD studies without tolvaptan.

Methods: This was a pooled, longitudinal analysis of data from 8 tolvaptan clinical trials and 5 studies without tolvaptan (natural history or SOC) in ADPKD. Data from subjects who participated in multiple studies were linked for longer follow-up. Outcomes were rates of change in estimated glomerular filtration rate (eGFR) and TKV over 5.5 years. To control for heterogeneity in disease characteristics between tolvaptan and SOC treatment groups, analysis populations matched for baseline demographic and disease characteristics were constructed.

Results: Matched analysis ( 1186 in each treatment group) indicated that tolvaptan slowed annualized eGFR decline by 1.01 ml/min per 1.73 m ( < 0.001) versus SOC over 5.5 years. An analysis conducted on the full, unmatched data set (tolvaptan: 2928; SOC: 4189) confirmed significant reduction in annual eGFR decline. Among subjects with TKV data, TKV was significantly reduced at years 1, 3, and 5 for tolvaptan versus SOC in both matched and full data sets.

Conclusion: Comparison of a pooled tolvaptan cohort to a pooled control cohort with ADPKD supports longer-term treatment effects of tolvaptan.

Citing Articles

Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis.

Chebib F, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S Kidney Med. 2025; 7(1):100935.

PMID: 39810815 PMC: 11731472. DOI: 10.1016/j.xkme.2024.100935.

A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.

Stanajic-Petrovic G, Keck M, Barbe P, Urman A, Correia E, Isnard P J Am Soc Nephrol. 2024; 36(2):181-192.

PMID: 39431458 PMC: 11801765. DOI: 10.1681/ASN.0000000505.

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.

Yamazaki M, Kawano H, Miyoshi M, Kimura T, Takahashi K, Muto S Int J Mol Sci. 2024; 25(4).

PMID: 38396765 PMC: 10888637. DOI: 10.3390/ijms25042088.

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.

Lioudis M, Zhou X, Davenport E, Nunna S, Krasa H, Oberdhan D BMC Nephrol. 2023; 24(1):182.

PMID: 37349694 PMC: 10286436. DOI: 10.1186/s12882-023-03247-6.

Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.

Chebib F, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D Kidney Med. 2023; 5(6):100639.

PMID: 37250503 PMC: 10220412. DOI: 10.1016/j.xkme.2023.100639.

References

Stevens L, Schmid C, Greene T, Zhang Y, Beck G, Froissart M . Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010; 56(3):486-95. PMC: 2926290. DOI: 10.1053/j.ajkd.2010.03.026. View

Nowak K, You Z, Gitomer B, Brosnahan G, Torres V, Chapman A . Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2017; 29(2):571-578. PMC: 5791072. DOI: 10.1681/ASN.2017070819. View

Torres V, Higashihara E, Devuyst O, Chapman A, Gansevoort R, Grantham J . Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016; 11(5):803-811. PMC: 4858477. DOI: 10.2215/CJN.06300615. View

Yu A, Shen C, Landsittel D, Grantham J, Cook L, Torres V . Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019; 95(5):1253-1261. PMC: 6478515. DOI: 10.1016/j.kint.2018.12.023. View

Schrier R, Abebe K, Perrone R, Torres V, Braun W, Steinman T . Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014; 371(24):2255-66. PMC: 4343258. DOI: 10.1056/NEJMoa1402685. View

Chapman A, Bost J, Torres V, Guay-Woodford L, Bae K, Landsittel D . Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012; 7(3):479-86. PMC: 3302672. DOI: 10.2215/CJN.09500911. View

Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Dandurand A . Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2017; 32(7):1262. DOI: 10.1093/ndt/gfx079. View

Irazabal M, Rangel L, Bergstralh E, Osborn S, Harmon A, Sundsbak J . Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2014; 26(1):160-72. PMC: 4279733. DOI: 10.1681/ASN.2013101138. View

Torres V, Chapman A, Perrone R, Bae K, Abebe K, Bost J . Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2011; 81(6):577-85. PMC: 3580956. DOI: 10.1038/ki.2011.411. View

10.

Perrone R, Chapman A, Oberdhan D, Czerwiec F, Sergeyeva O, Ouyang J . The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney Int Rep. 2020; 5(6):801-812. PMC: 7271939. DOI: 10.1016/j.ekir.2020.03.011. View

11.

Boertien W, Meijer E, de Jong P, Ter Horst G, Renken R, van der Jagt E . Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Am J Kidney Dis. 2015; 65(6):833-41. DOI: 10.1053/j.ajkd.2014.11.010. View

12.

Cornec-Le Gall E, Audrezet M, Chen J, Hourmant M, Morin M, Perrichot R . Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013; 24(6):1006-13. PMC: 3665389. DOI: 10.1681/ASN.2012070650. View

13.

Cho Y, Tong A, Craig J, Mustafa R, Chapman A, Perrone R . Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2020; 77(2):255-263. DOI: 10.1053/j.ajkd.2020.05.024. View

14.

Torres V, Chapman A, Devuyst O, Gansevoort R, Grantham J, Higashihara E . Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367(25):2407-18. PMC: 3760207. DOI: 10.1056/NEJMoa1205511. View

15.

Torres V, Abebe K, Chapman A, Schrier R, Braun W, Steinman T . Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014; 371(24):2267-76. PMC: 4284824. DOI: 10.1056/NEJMoa1402686. View

16.

Dicks E, Ravani P, Langman D, Davidson W, Pei Y, Parfrey P . Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol. 2007; 1(4):710-7. DOI: 10.2215/CJN.01581105. View

17.

Boertien W, Meijer E, de Jong P, Bakker S, Czerwiec F, Struck J . Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013; 84(6):1278-86. DOI: 10.1038/ki.2013.285. View

18.

Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Lee J . Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020; 16(1):48-58. PMC: 7792652. DOI: 10.2215/CJN.10250620. View

19.

Hateboer N, v Dijk M, Bogdanova N, Coto E, Saggar-Malik A, San Millan J . Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999; 353(9147):103-7. DOI: 10.1016/s0140-6736(98)03495-3. View

20.

Grantham J, Torres V, Chapman A, Guay-Woodford L, Bae K, King Jr B . Volume progression in polycystic kidney disease. N Engl J Med. 2006; 354(20):2122-30. DOI: 10.1056/NEJMoa054341. View